New evidence supports closer follow-up for some patients and less surveillance for others, according to a task force of the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal
A meta-analysis of inflammatory bowel disease (IBD) studies did find improvements in patient-reported symptoms and quality of life associated with cannabis and cannabinoids.
However, patients who were obese but did not have fatty liver disease were not at increased risk of hospitalization for COVID-19, according to a study of healthy people in a U.K. database who underwent MRI assessment of liver fat markers.
Women have a significantly lower risk of developing nonalcoholic fatty liver disease (NAFLD) but a higher risk of developing advanced fibrosis from NAFLD, according to a systematic review and meta-analysis.
A randomized trial found that median length of hospital stay was 40.0 hours in the antibiotic group and 45.8 hours in the placebo group, with no significant between-group differences in adverse events or readmissions.
Decompensation-free survival improved in patients with cirrhosis and portal hypertension who received beta-blockers versus placebo, largely due to a decrease in ascites.
A randomized trial of three polyethylene glycol regimens found that more patients tolerated and were willing to repeat low-volume same-day or split-dose prep compared to high-volume split-dose regimens.
A retrospective cohort study looked at patients with cirrhosis who were enrolled in Medicare and had had more than four outpatient visits over 180 days.
A survey of internists showed that 79% inappropriately recommended stopping proton-pump inhibitors (PPIs) in a prevention scenario focusing on high-risk upper gastrointestinal bleeding.
Although this study highlights a potential role of HPV status in the prognosis of esophageal adenocarcinoma, “the use of HPV as a predictive marker for treatment remains unproven,” an accompanying commentary